Pre-Made Denileukin Diftitox Biosimilar, Fusion Protein targeting IL1RL2 fused with human IL2 (interleukin 2, IL-2): Recombinant therapeutic protein targeting IL-1Rrp2/IL-36R/IL1R-rp2/IL1RRP2 for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-INN-799

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-INN-799 Category Tag

Product Details

Pre-Made Denileukin Diftitox Biosimilar, Fusion Protein targeting IL1RL2 fused with human IL2 (interleukin 2, IL-2): Recombinant therapeutic protein targeting IL-1Rrp2/IL-36R/IL1R-rp2/IL1RRP2 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Denileukin diftitox (trade name Ontak) was an antineoplastic agent, an engineered protein combining interleukin-2 and diphtheria toxin. Denileukin diftitox could bind to interleukin-2 receptors[1] and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some leukemias and lymphomas, malignant cells express these receptors, so denileukin diftitox can target these.

Denileukin diftitox is a recombinant cytotoxic protein based on a combination of diphtheria toxin fragments and interleukin-2 used to treat cutaneous T-cell lymphoma by targeting the interleukin-2 receptor. Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes.

Products Name (INN Index)

Pre-Made Denileukin Diftitox Biosimilar, Fusion Protein targeting IL1RL2 fused with human IL2 (interleukin 2, IL-2): Recombinant therapeutic protein targeting IL-1Rrp2/IL-36R/IL1R-rp2/IL1RRP2

INN Name

denileukin diftitox

Target

IL1RL2

Format

Fusion Protein

Derivation

Corynebacterium diphtheriae Human

Species Reactivity

Human

CH1 Isotype

Fusion – aldifitox : diphteriatoxin (AB toxin) 1-387 – IL2 (interleukin 2, IL-2) 1-133

VD LC

Fusion – aldifitox : diphteriatoxin (AB toxin) 1-387 – IL2 (interleukin 2, IL-2) 1-133

Highest_Clin_Trial (Jan '20)

NA

Est. Status

NA

100% SI Structure

NA

99% SI Structure

NA

95-98% SI Structure

NA

Year Proposed

NA

Companies

Eisai?Co.?Ltd. (Tokyo Japan)

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

IL1RL2

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide